FDA Class II Rule for Alzheimer's Pathology Tests

Published April 2026 | Regulatory Change Alert

If you manufacture, distribute, or are developing an Alzheimer's disease pathology assessment test, the FDA just changed the regulatory landscape under your feet — and the practical consequences are worth working through carefully.

On April 22, 2026, FDA published a final rule in the Federal Register classifying Alzheimer's disease pathology assessment tests into Class II (Special Controls) under 21 CFR. The rule was published under Docket No. FDA-2024-N-XXXX, Federal Register document 2026-07860. This is not a proposed rule. It is final, and it carries real compliance obligations for anyone in this device category.

The lesson here is not simply "update your classification paperwork." It is that FDA has now drawn a clear regulatory line around a device category that was either unclassified or operating in a more ambiguous space — and the special controls attached to Class II status have specific analytical and clinical performance expectations baked in. If your submission strategy, design history file, or clinical evidence package was built around a different assumption about classification, you have work to do.

What FDA Actually Did — and Why It Matters

FDA's authority to classify devices into Class II comes from section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Class II is the middle tier: more oversight than Class I, but not the full premarket approval (PMA) burden of Class III. The tradeoff is that Class II devices must comply with special controls — specific performance standards, labeling requirements, and postmarket surveillance obligations that FDA determines are sufficient, alongside general controls, to provide reasonable assurance of safety and effectiveness.

For Alzheimer's disease pathology assessment tests, FDA determined that Class III (PMA) is not necessary, and that Class II with special controls is the appropriate home. That determination matters because it tells you exactly what kind of evidence FDA expects — not just now, but going forward for every 510(k) submission in this category.

According to FDA's published rationale, the agency concluded that the special controls it is imposing will provide a reasonable assurance of safety and effectiveness for this device type. In regulatory language, that phrase carries weight: it means FDA has assessed the risk profile of the device and concluded that the combination of general controls and the new special controls is adequate to manage it.

What Are "Special Controls" and What Do They Require Here?

Special controls under Class II can include a range of requirements depending on the device type. For diagnostics — and Alzheimer's pathology assessment tests are diagnostics — special controls typically address:

• Analytical performance testing: Sensitivity, specificity, precision, accuracy, and interference studies
• Clinical performance requirements: Studies demonstrating how the device performs against a reference standard (in this case, likely neuropathological confirmation of amyloid or tau pathology)
• Labeling requirements: What the intended use must say, what limitations must be disclosed, and how results should be interpreted
• Postmarket requirements: Any ongoing surveillance or complaint handling obligations specific to the device type

The codified special controls for this specific device type are now part of the classification regulation itself. That means they are binding, not advisory. If your device falls within the product code and classification description FDA has established, your 510(k) submission — or De Novo request if you are establishing a new predicate — must address each special control explicitly.

I have seen companies underestimate the gap between "we have clinical data" and "we have clinical data that satisfies the special controls as written." Those are not always the same thing, and finding that out mid-review costs real time.

The Regulatory Pathway: What Changes for 510(k) Submitters

Before this final rule, a manufacturer seeking clearance for an Alzheimer's disease pathology assessment test would have needed to identify a predicate device and demonstrate substantial equivalence. The question of what performance data FDA expected was more a function of precedent and reviewer discretion than codified standards.

Now, the special controls define the floor. A 510(k) submission in this category must:

1. Identify the device as falling within the new classification regulation
2. Demonstrate compliance with each enumerated special control
3. Provide the analytical and clinical performance data FDA has specified
4. Meet the labeling requirements built into the classification

This is actually a more predictable environment for manufacturers than the pre-rule status quo, even if it feels like more work. When the standard is codified, you can design your development program around it from the beginning rather than guessing what a reviewer will ask.

The table below summarizes how the regulatory landscape shifts under this rule:

Effective Date and Compliance Deadlines

The final rule was published April 22, 2026. As with most FDA device classification rules, the effective date follows publication in the Federal Register. Manufacturers with devices already on the market in this category should pay close attention to any transitional provisions FDA included in the rule — these define whether you need to submit a new 510(k) to retain clearance or whether an existing clearance remains valid under the new classification framework.

If you are in development or have a submission in progress, the special controls now govern your submission regardless of when your development program started. FDA does not grandfather development-stage devices against a new classification rule the way it sometimes handles devices already in commercial distribution.

In my view, the highest-priority action for any company in this space right now is a gap assessment: compare your current evidence package against the codified special controls, identify what is missing or insufficient, and build a remediation plan before you file. A 510(k) that lands on an FDA reviewer's desk without addressing the special controls is going to generate deficiency letters at best, and a not-substantially-equivalent (NSE) determination at worst.

Why Alzheimer's Diagnostics Are Under This Kind of Scrutiny

Alzheimer's disease pathology assessment tests occupy a genuinely high-stakes clinical space. The downstream consequences of a false positive — a patient told they have amyloid or tau pathology when they do not — can lead to unnecessary treatment, psychological harm, and significant financial cost. A false negative in a population being considered for disease-modifying therapy can mean a patient misses a treatment window.

According to the Alzheimer's Association, an estimated 6.9 million Americans aged 65 and older were living with Alzheimer's dementia in 2024, with that number projected to nearly double to 13 million by 2050. The diagnostic market serving this population is growing fast — FDA's decision to establish a clear Class II framework with specific performance standards reflects the agency's recognition that the stakes here are high enough to warrant codified oversight.

There is also a broader regulatory context worth noting. FDA has been working through a wave of Alzheimer's-related regulatory decisions over the last several years, including the approvals of lecanemab and donanemab for early Alzheimer's disease, both of which require confirmation of amyloid pathology for appropriate patient selection. A diagnostic test that mis-identifies eligible patients for these therapies is not just a device problem — it is a therapy safety problem. That context almost certainly informed FDA's decision to move quickly to establish clear standards.

What "Reasonable Assurance of Safety and Effectiveness" Means for Your Design

When FDA says that Class II with special controls provides "reasonable assurance of safety and effectiveness," that phrase has specific regulatory meaning under 21 CFR 860.7. It does not mean the device must be perfect. It means the device must perform consistently with its intended use, within clearly characterized limitations, with those limitations disclosed in labeling.

For an Alzheimer's disease pathology assessment test, this likely means:

• Sensitivity and specificity thresholds defined by the special controls, likely benchmarked against neuropathological confirmation
• Analytical precision requirements across the measurement range the device claims
• Interference studies covering conditions common in the target population (hemolysis, lipemia, heterophilic antibodies, and potentially other concurrent conditions or medications)
• Labeling that accurately frames the intended use — including whether the test is intended for diagnosis, for patient selection for therapy, or for monitoring

One thing I consistently tell clients: the intended use statement in your labeling is load-bearing. It determines which special controls apply, how FDA evaluates your clinical data, and what post-market surveillance obligations you carry. Get the intended use right before you build anything else.

Practical Compliance Guidance: What to Do Now

Whether you have a device in development, a submission in preparation, or an existing cleared device you are now managing under a new classification framework, here is how I would prioritize the work:

1. Pull the final rule and read the codified special controls. The special controls are part of the CFR now, which means they are public and specific. The Federal Register document (2026-07860, published April 22, 2026) is the primary source. Read it alongside the product code FDA has assigned to this device type.

2. Do a gap assessment against your current evidence package. Map each special control requirement to the data you have. Where the data does not exist or does not clearly satisfy the requirement, flag it. Do this before you decide on a submission timeline — you cannot compress study time that you do not have.

3. Revisit your intended use statement. If your intended use was drafted before this rule, it may need to be tightened or broadened depending on what the special controls say about device claims. An intended use that overreaches what your evidence supports, or that is inconsistent with the classification, will create problems in review.

4. Assess whether you need a new 510(k) for an existing marketed device. If you have a device already in commercial distribution in the U.S. and FDA's rule treats it as now classified into Class II, you need to understand whether your existing clearance is sufficient or whether you need to submit a new 510(k) that addresses the special controls. This is a question for your regulatory counsel, and the answer matters for your commercial continuity.

5. Build the special controls into your design history file going forward. For devices still in development, the special controls should now be part of your design inputs. If you are using a quality management system — ideally one built around ISO 13485:2016 requirements for design and development controls — the special control requirements belong in your design input records as regulatory requirements the device must meet.

The Broader Signal: FDA Is Building Out the Alzheimer's Diagnostic Framework

This classification rule is part of a larger pattern. FDA is systematically building the regulatory infrastructure for Alzheimer's diagnostics to match the growing clinical pipeline. Amyloid PET imaging guidance, CSF biomarker test approvals, and now this classification rule for pathology assessment tests — together they represent FDA drawing clear lines around a category that, five years ago, had almost no codified standards.

If you are working in the neurodegenerative disease diagnostic space more broadly, the practical implication is that the era of navigating this category by precedent and reviewer discretion is narrowing. FDA is codifying its expectations, which makes the path more predictable for manufacturers who do the work — and more punishing for those who do not.

In my experience working with diagnostic device manufacturers, the companies that get into trouble are not usually the ones that lack good science. They are the ones that let their regulatory strategy lag behind their development timeline. When a new classification rule drops, that gap closes fast.

Summary: The Three Things That Matter Most

If you take nothing else from this article, take these three things.

First, this rule is final and codified — the special controls are now part of the CFR and apply to every submission in this device category. There is no comment period, no phase-in ambiguity, and no reviewer discretion around whether they apply to you.

Second, the analytical and clinical performance requirements in the special controls define the minimum evidentiary floor for 510(k) clearance. If your evidence package was built before this rule, it may not clear that floor, and finding out during review is expensive.

Third, for any device already in commercial distribution, the question of whether you need a new 510(k) under the new classification framework needs a concrete answer before your next annual review cycle — not after a compliance conversation with FDA.

If you want help working through the gap assessment or building a submission strategy against the new special controls, this is the kind of problem Certify Consulting works through with device manufacturers every week.

Last updated: 2026-05-01

Source: Federal Register, Vol. 91, Doc. 2026-07860, published April 22, 2026. Available at federalregister.gov.